Lillys EloraTZP tops Zepbound in mid-stage obesity trial
The highest dose of retatrutide produced average weight loss of up to 28.3 percent over 80 weeks in patients without diabetes in a late-stage trial. EloraTZP also reduced blood sugar levels, lowering A1C by as much as 2.9 percent, compared with 2.4 percent for tirzepatide alone, according to data presented at the European Association for the Study of Diabete